The overall objective of the program is to train physicians in head and neck oncology for a career that combines laboratory research with clinical practice. This unique Research Training Program at the University of Pittsburgh enables trainees to develop both basic research and clinical skills. Potential trainees are selected from the outstanding pool of candidates that apply to the Residency Program in Otolaryngology. Trainees can select preceptors with research interests that span a variety of disciplines including pharmacology, molecular biology, immunology, and human genetics. Two, 3- month protected research blocks are provided in the PGY-3 and PGY-4 years to allow trainees to rotate through potential training laboratories. The PGY-5 and PGY-6 years are spent entirely in the preceptor's basic science laboratory. During this protected research time, trainees can participate in a formal Research Methodology Training Program at the University of Pittsburgh (formerly K30, now CTSI). Following the second laboratory year, trainees complete their final year of clinical training (PGY-7) that consists primarily of head and neck surgery. To attract the highest quality applicants, trainees pursue a modified clinical training program that allows them to acquire subspecialty head and neck oncology clinical training during the 7-year training period so that additional, clinical fellowship training is not necessary. One new trainee will be admitted to our program each year. Trainees are encouraged to develop their own independent research program as they transition to junior faculty. The ultimate goal is for trainees to establish themselves in as academic environment not only as clinician researchers, but also as translational head and neck scientists.

Public Health Relevance

This program provides an important opportunity for head and neck surgeons to acquire the necessary training to become physician-scientists. Head and neck cancer is a frequently fatal malignancy with few therapeutic options. It is rare for a basic scientist to elect to focus their career on the investigation of head and neck cancer. Clinicians, including otolaryngologists-head and neck surgeons, do not have sufficient training in basic and translational research approaches during the standard residency and/or fellowship to embark on an independent research career. This unique training program takes advantage of the substantial clinical and research resources and at the University of Pittsburgh focused on head and neck cancer. We have demonstrated a successful track record of preparing physicians for academic careers as head and neck oncologists as we continue to refine the training program to take advantage of new opportunities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA060397-17
Application #
8136716
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (M1))
Program Officer
Lim, Susan E
Project Start
1994-06-01
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
17
Fiscal Year
2011
Total Cost
$140,274
Indirect Cost
Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Shayan, Gulidanna; Srivastava, Raghvendra; Li, Jing et al. (2017) Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology 6:e1261779
Srivastava, Raghvendra M; Trivedi, Sumita; Concha-Benavente, Fernando et al. (2017) CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res 23:707-716
Kansy, Benjamin A; Concha-Benavente, Fernando; Srivastava, Raghvendra M et al. (2017) PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res 77:6353-6364
Panebianco, Federica; Kelly, Lindsey M; Liu, Pengyuan et al. (2017) THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proc Natl Acad Sci U S A 114:2307-2312
Albergotti, William G; Gooding, William E; Kubik, Mark W et al. (2017) Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. JAMA Otolaryngol Head Neck Surg 143:542-548
Huyett, Phillip; Gilbert, Mark; Liu, Lijun et al. (2017) A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma. J Vis Exp :
Moy, Jennifer D; Moskovitz, Jessica M; Ferris, Robert L (2017) Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 76:152-166

Showing the most recent 10 out of 52 publications